Experienced in Angioimmunoblastic T-cell Lymphoma

Dr. Robert M. Droder

University Of Texas Health Science Center At Tyler-Facility-Physician
Tyler, TX
Experienced
in Angioimmunoblastic T-cell Lymphoma
Specialties:Hematology Oncology | Hematology | Oncology
OverviewInsuranceLocationsClinical Research

Overview

Robert Droder is a Hematologist Oncology specialist and a Hematologist in Tyler, Texas. Dr. Droder and is rated as an Experienced provider by MediFind in the treatment of Angioimmunoblastic T-cell Lymphoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Familial Colorectal Cancer, Childhood Iron Deficiency Anemia, and Bone Marrow Aspiration.

His clinical research consists of participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
The University Of Texas Health Science Center At Tyler
UT Health East Texas Jacksonville Hospital
UT Health East Texas Tyler Regional Hospital
UT Health East Texas Athens Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Humana

Locations

UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER-FACILITY-PHYSICIAN
721 -a Clinic Dr, Hope Cancer Center Tyler, Tyler, TX 75701
903-284-2273
Other Locations
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER-FACILITY-PHYSICIAN
1000 S Beckham Ave, Ut Health Science Center At Tyler, Tyler, TX 75701
903-877-7200
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER-FACILITY-PHYSICIAN
102 W Henderson St, Ut Health Northeast Overton, Overton, TX 75684
903-834-0201
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER-FACILITY-PHYSICIAN
11937 Us Hwy 271, Tyler, TX 75708
903-877-7200

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Biological
Study Phase: Phase 3
View 2 Less Clinical Trials
Similar Doctors
Expertise in
47
conditions
Dr. Joseph T. Martins
Hematology Oncology | Hematology | Oncology
Expertise in
47
conditions
Dr. Joseph T. Martins
Hematology Oncology | Hematology | Oncology

University Of Texas Health Science Center At Tyler-Facility-Physician

11937 Us Hwy 271, 
Tyler, TX 
 (7.4 mi)
903-877-7200
Languages Spoken:
English
See accepted insurances

Joseph Martins is a Hematologist Oncology specialist and a Hematologist in Tyler, Texas. Dr. Martins and is rated as a Distinguished provider by MediFind in the treatment of Angioimmunoblastic T-cell Lymphoma. His top areas of expertise are Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, Lung Cancer, and Thrombocytopenia.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile